Resona Asset Management Co. Ltd. Acquires 5,144 Shares of Eli Lilly and Company $LLY

Key Points

• Resona Asset Management increased its Eli Lilly stake by 2.0% in Q1, buying 5,144 more shares and bringing its total holding to 258,768 shares valued at about $236.4 million.
• Wall Street sentiment remains constructive, with firms like Barclays, Cantor Fitzgerald, and RBC raising price targets and analysts maintaining an overall Moderate Buy rating.
• Eli Lilly continues to post strong operating results, reporting EPS of $8.55 and 55.5% revenue growth in its latest quarter, while also announcing a quarterly dividend of $1.73 per share.

Resona Asset Management Co. Ltd. boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 258,768 shares of the company's stock after buying an additional 5,144 shares during the quarter. Eli Lilly and Company accounts for approximately 1.2% of Resona Asset Management Co. Ltd.'s holdings, making the stock its 12th biggest position. Resona Asset Management Co. Ltd.'s holdings in Eli Lilly and Company were worth $236,382,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. M.E. Allison & CO. Inc. raised its holdings in shares of Eli Lilly and Company by 0.7% during the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock valued at $1,587,000 after purchasing an additional 10 shares during the last quarter. Tanager Wealth Management LLP boosted its holdings in Eli Lilly and Company by 2.6% in the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock worth $424,000 after purchasing an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 1.5% in the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock worth $710,000 after purchasing an additional 10 shares during the last quarter. Wealthspan Partners LLC grew its position in Eli Lilly and Company by 0.5% in the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock worth $2,268,000 after purchasing an additional 10 shares during the period. Finally, G&S Capital LLC grew its position in Eli Lilly and Company by 2.0% in the 4th quarter. G&S Capital LLC now owns 501 shares of the company's stock worth $538,000 after purchasing an additional 10 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan and RBC both raised their price targets on Eli Lilly, reinforcing Wall Street’s view that the company still has meaningful upside despite its rich valuation.
• Positive Sentiment: LLY received another boost after its eczema treatment was approved in Canada, adding to the company’s growing non-obesity pipeline and supporting the bull case beyond weight-loss drugs. Article Title
• Positive Sentiment: Several articles highlighted Eli Lilly’s strong GLP-1 and obesity momentum, noting record highs and ongoing investor enthusiasm around Mounjaro, Zepbound, and the broader obesity market.
• Neutral Sentiment: Commentary pieces asked whether it is “too late” to buy LLY and whether the stock is too expensive, but these were largely opinion-driven and did not change the underlying business outlook.
• Neutral Sentiment: Healthcare stocks were broadly weaker late in the day, which may have added some sector-level drag on LLY even as company-specific news remained constructive. Article Title
• Negative Sentiment: Tampa General filed suit against Eli Lilly over pulled 340B discounts, creating a regulatory/legal overhang that could raise investor concerns about drug pricing and hospital reimbursement disputes. Article Title

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LLY. Barclays increased their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a report on Monday, May 4th. Cantor Fitzgerald lifted their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an "overweight" rating in a report on Monday. UBS Group reiterated a "buy" rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Morgan Stanley increased their target price on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an "overweight" rating in a report on Wednesday. Finally, Royal Bank Of Canada raised their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $1,255.89.

Eli Lilly and Company Trading Down 1.4%

Shares of Eli Lilly and Company stock opened at $1,218.76 on Thursday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45. The company's fifty day simple moving average is $1,085.08 and its 200-day simple moving average is $1,031.42. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market capitalization of $1.15 trillion, a PE ratio of 43.30, a P/E/G ratio of 1.54 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period in the prior year, the business posted $3.34 EPS. Eli Lilly and Company's revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 35.7 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.